BioSpace News Archive

Vaccinex, Inc. announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 to 10:25 am Eastern Time in New York City, NY and invites investors to participate in one-on-one meetings that same day.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial.

Elevar Therapeutics, Inc. announced its participation plans for the 2023 American Society of Clinical Oncology Annual Meeting in Chicago and the 2023 BIO International Convention in Boston.

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices.

The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy.

Sarah Cannon Research Institute announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology Annual Meeting June 2-6, 2023.

Laxxon Medical announced today its participation in the 2023 BIO International Convention.

LAVA Therapeutics N.V. today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, announced its management team will participate in fireside chats at two upcoming investor conferences.

T-knife Therapeutics, Inc. today announced presentation of a poster titled, “MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to human-derived MAGE-A1 TCRs” at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held from May 31 – June 3, 2023 in Paris, France.